Trial Profile
A Phase I/II Study of Blinatumomab in Combination With Pembrolizumab (MK-3475) for Adults With Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia With High Bone Marrow Lymphoblast Percentage
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Pembrolizumab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 28 Aug 2023 Planned End Date changed from 1 Aug 2023 to 31 Dec 2025.
- 28 Aug 2023 Planned primary completion date changed from 1 Aug 2022 to 31 Dec 2025.
- 28 Aug 2023 Status changed from discontinued to active, no longer recruiting.